{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000120","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.473044+00:00","generated_at":"2026-05-31T06:14:57.060676+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5","bullets":["Company began investor roadshow on September 5, 2024, with an updated investor slide deck.","Deck includes new data from the Phase 1 trial of NX-5948 for various B-cell malignancies.","No specific numerical results (e.g., response rates, safety) are disclosed in this 8-K filing.","NX-5948 is a targeted protein degrader; the full presentation may contain efficacy/safety details."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000120","json":"https://secwatch.observer/filing/0001549595-24-000120.json","markdown":"https://secwatch.observer/filing/0001549595-24-000120.md","text":"https://secwatch.observer/filing/0001549595-24-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/0001549595-24-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/nrix-20240905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:14:57.060676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}